What was the nature of the Imunon (IMNN) share grant to Susan Eylward?

Eylward received 14,696 Imunon common shares as a grant in lieu of cash for 50% of her 2025 annual cash bonus, effectively replacing part of her cash compensation with equity at a grant price of $1.72 per share.

Imunon (IMNN) counsel gets stock bonus, then sells 11,800 shares

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Imunon, Inc. General Counsel and Corporate Secretary Susan Eylward reported both an equity award and a stock sale. On June 25, 2026, she acquired 14,696 shares of common stock at $1.72 per share as a grant in lieu of cash for 50% of her 2025 annual cash bonus. On June 29, 2026, she executed an open-market sale of 11,800 shares at a weighted average price of $1.752 per share, with individual sale prices ranging from $1.73 to $1.80 per share. Following the sale, she directly owned 2,896 shares of Imunon common stock.

Insights

Comp-related share grant partly offset by a modest open-market sale.

Susan Eylward, General Counsel and Corporate Secretary of Imunon, Inc., received 14,696 shares of common stock at $1.72 per share as equity in lieu of 50% of her 2025 cash bonus. This is a standard compensation mechanism that increases her equity exposure.

Four days later, she executed an open-market sale of 11,800 shares at a weighted average price of $1.752 per share, within a $1.73–$1.80 price range, leaving her with 2,896 shares directly held. The filing does not indicate any derivative positions, and this combination of grant and subsequent partial sale appears routine in size and structure.

Insider Trade Summary

Net Seller: 11,800 shares ($20,674)

Net Sell 2 txns

Insider Eylward Susan

Role General Counsel and Corp Sec

Sold 11,800 shs ($21K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,800	$1.752	$21K
Grant/Award	Common Stock	14,696	$1.72	$25K

Holdings After Transaction: Common Stock — 2,896 shares (Direct, null)

Footnotes (1)

Stock granted in lieu of cash for 50% of 2025 annual cash bonus Reflects a weighted average sale price of $1.752 per share, at prices ranging from $1.73 to $1.80 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price.

Key Figures

Open-market sale: 11,800 shares at $1.752 Equity grant: 14,696 shares at $1.72 Shares remaining: 2,896 shares +1 more

4 metrics

Open-market sale 11,800 shares at $1.752 Weighted average sale price on June 29, 2026; prices $1.73–$1.80

Equity grant 14,696 shares at $1.72 Stock granted June 25, 2026 in lieu of 50% 2025 cash bonus

Shares remaining 2,896 shares Directly owned after June 29, 2026 sale

Net shares sold 11,800 shares Net-sell direction per transactionSummary

Key Terms

open-market sale, grant, award, or other acquisition, weighted average sale price, annual cash bonus

4 terms

open-market sale financial

"transaction_action: "open-market sale" for 11,800 shares of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition" for 14,696 shares"

weighted average sale price financial

"Reflects a weighted average sale price of $1.752 per share"

annual cash bonus financial

"Stock granted in lieu of cash for 50% of 2025 annual cash bonus"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:34 PM Accepted by SEC EDGAR 06/29/2026 - 04:34 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eylward Susan

(Last)

(First)

(Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE

NEW JERSEY

08648

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	General Counsel and Corp Sec

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/25/2026		A		14,696⁽¹⁾	A	$1.72	14,696	D
Common Stock	06/29/2026		S		11,800	D	$1.752⁽²⁾	2,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Stock granted in lieu of cash for 50% of 2025 annual cash bonus

2. Reflects a weighted average sale price of $1.752 per share, at prices ranging from $1.73 to $1.80 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price.

	/s/ Susan Eylward	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Imunon (IMNN) General Counsel Susan Eylward report?

Susan Eylward reported two transactions: a grant of 14,696 Imunon common shares on June 25, 2026, and an open-market sale of 11,800 shares on June 29, 2026, at a weighted average price of $1.752 per share.

How many Imunon (IMNN) shares did Susan Eylward sell and at what price?

She sold 11,800 Imunon common shares in an open-market transaction at a weighted average price of $1.752 per share, with individual sale prices ranging from $1.73 to $1.80, as disclosed in the Form 4 footnote.

How many Imunon (IMNN) shares does Susan Eylward hold after these transactions?

After the June 29, 2026 open-market sale, Susan Eylward directly holds 2,896 shares of Imunon common stock, according to the post-transaction ownership figure disclosed in the Form 4 filing.

Were Susan Eylward’s Imunon (IMNN) transactions open-market trades or compensation grants?

The Form 4 shows both: a compensation-related grant of 14,696 shares classified as a grant or award acquisition, and an open-market sale of 11,800 shares executed at market prices between $1.73 and $1.80 per share.